RxDoctor Payments Data

Neal Kansara

Ophthalmology · Bradenton, FLNPI 1619409380

Payments from drug & device makers

$5,547in general payments, 2019–2025

Across 128 payments — averaging $43.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
  • AbbVie$2K
  • Alcon$737
  • Sight Sciences, Inc.$374
  • Harrow Eye, LLC$152
  • Ivantis, Inc$143
  • plus $489 from 8 others

What the payments were for

  • Travel & lodging$1,39925%
  • Food & beverage$4,13274%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,547 in reported general payments places this provider in the 70th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$443,226
Medicare patients
1,459
Services billed
4,085

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost179$96,622
ProlensaBromfenac Sodium125$44,670
RestasisCyclosporine31$44,518
RhopressaNetarsudil Mesylate85$36,454
BesivanceBesifloxacin Hcl120$26,575
Alphagan PBrimonidine Tartrate46$24,921
CombiganBrimonidine Tartrate/Timolol39$17,446
VyzultaLatanoprostene Bunod28$17,395
SimbrinzaBrinzolamide/Brimonidine Tart56$14,806
Dorzolamide-TimololDorzolamide/Timolol/Pf62$13,101
RocklatanNetarsudil Mesylat/Latanoprost18$13,084
Prednisolone Acetate262$13,000
Brimonidine Tartrate212$10,893
Latanoprost836$7,508
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol32$6,638

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$1,717$183,507295 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Besivance, Lotemax Sm$1,934$74,482258 claims
Bausch & Lomb Americas Inc.Vyzulta$104$17,39528 claims
AlconSimbrinza$737$14,80656 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →